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Background
The Vaccine Research Center has developed a 3 DNA
prime, recombinant adenovirus serotype 5 vector (rAd5)
boost vaccination regimen that is immunogenic in HIV-
uninfected individuals. Vaccination of HIV-infected indi-
viduals with potent immunogens offers the possibility of
enhancing the magnitude, quality, and breadth of
response compared to existing HIV immunity.
Methods
Seventeen HIV-infected men on HAART with undetecta-
ble viral loads (<50 copies/ml) and CD4+ T cells counts
>350 cells/mm3 were enrolled in VRC 101. Eleven of 12
subjects randomized to the vaccination arm completed all
immunizations; one did not receive the rAd5 boost. Four
of 5 placebo recipients completed mock immunizations.
Sixteen subjects completed 48 weeks of follow-up; 1 con-
trol subject discontinued after Week 36. Immunologic
effects of vaccination were assessed based on the differ-
ence between pre-vaccination and 1 month post-rAd5
boost responses.
Results
Vaccination of HIV-infected individuals was well-toler-
ated; reactogenicity was similar to that seen in HIV-unin-
fected individuals. Viral loads remained undetectable in
all but one vaccinee who showed transient low level
virema (<100 copies/ml) during this study. No change in
CD4+ T cell count was apparent in either controls or vac-
cinees. Vaccination induced significant increases in the
frequency of IFN-gamma ELISpot response to Clade B Gag
(P < 0.005), Pol (P < 0.05), and Clade A (P < 0.005), B (P
< 0.005), and C Env (P < 0.05) overlapping 15 mer pep-
tides. This increase was in part due to an increase in
number of epitopes recognized. IFN-gamma ELISpot
responses to Clade B Nef, not targeted by Ad5 boost vac-
cination, were not significantly increased in vaccinees. No
significant change was observed in controls.
Conclusion
Pre-existing HIV-specific T cells responses can be safely
boosted with existing vaccine products. The magnitude of
these responses is large enough to allow the comparison
of pre-existing responses to vaccine-induced responses at
specific optimized epitopes and allow a systematic
approach to the study of therapeutic vaccination in HIV-
infected individuals.
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